Gefitinib, an EGFR inhibitor, can block AREG-EGFR signaling to relieve bone destruction in MM [31, 61], while JQ1 acts on BMSCs to disturb CXCL8 synthesis and reveal anti-tumor efficacy [52]. Here, EGFR is linked to Miyoshi myopathy.